BioStem Technologies (OTCMKTS:BSEM - Get Free Report) is projected to release its earnings data after the market closes on Monday, April 7th. Analysts expect BioStem Technologies to post earnings of $0.37 per share and revenue of $86.69 million for the quarter.
BioStem Technologies Trading Up 5.4 %
BSEM traded up $0.41 during trading hours on Wednesday, hitting $7.97. The company's stock had a trading volume of 56,546 shares, compared to its average volume of 59,298. BioStem Technologies has a fifty-two week low of $6.77 and a fifty-two week high of $28.26. The company has a 50-day simple moving average of $12.07 and a 200 day simple moving average of $13.68. The firm has a market capitalization of $133.12 million, a PE ratio of 11.72 and a beta of 0.09.
BioStem Technologies Company Profile
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Further Reading
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
